Immune Cell Engineering Market Report Scope & Overview:

The Immune Cell Engineering Market was valued at USD 4.18 Billion in 2025 and is expected to reach USD 21.18 Billion by 2035, growing at a CAGR of 17.60% from 2026-2035.

The Immune Cell Engineering Market covers the reagents, instruments and services used to modify T cells, NK cells and other immune cells so they can recognize and attack disease more effectively. This work underpins approved CAR-T therapies for blood cancers and a growing pipeline of cell therapies in development for solid tumors and autoimmune disease. Established life sciences tool suppliers provide the engineering reagents and manufacturing platforms used across these programs. Growing clinical and commercial validation of engineered cell therapies is extending demand further upstream, into the research tools and manufacturing capacity needed to develop the next generation of candidates.

⮞Thermo Fisher Scientific introduced the Gibco CTS DynaXS Single Use Bioreactor on May 4, 2026, a stirred-tank expansion system that extends its Cell Therapy Systems portfolio from process development batches to larger cGMP manufacturing runs. Launches of this kind from a major reagent and instrument supplier reflect the broader build-out of scalable manufacturing tools that engineered cell therapy programs increasingly rely on.

U.S. Immune Cell Engineering Market Outlook:

The U.S. Immune Cell Engineering Market was valued at USD 1.47 Billion in 2025 and is expected to reach USD 7.59 Billion by 2035, growing at a CAGR of 17.85% from 2026-2035.

The U.S. carries the largest share of regional immune cell engineering spending, anchored by pharmaceutical developers, academic cancer centers and specialized manufacturing sites. Commercial CAR-T therapies approved for blood cancers continue to post strong sales growth, reinforcing investment in engineering platforms for new indications including solid tumors and autoimmune disease. Continued clinical and commercial validation of engineered cell therapies is expected to support steady U.S. market growth through 2035.

⮞Lonza and Genetix Biotherapeutics announced on March 9, 2026, an extension of their commercial manufacturing agreement for the gene therapy Zynteglo, under which Lonza will increase capacity at its cell and gene therapy facility in Houston, Texas. Capacity additions at a U.S. manufacturing site illustrate the contract manufacturing build-out that supports engineered cell and gene therapy programs in the United States.

By Cell Type, T Cells Dominates the Immune Cell Engineering Market and NK Cells Grows Fastest

T cells hold the largest cell type share because every approved CAR-T therapy on the market today is built on engineered T cells, giving this cell type the deepest base of validated manufacturing processes, regulatory precedent and clinical experience. Pharmaceutical developers expanding engineered cell therapies into new cancer types and autoimmune indications continue to build primarily on this same established T cell platform rather than starting from an unproven alternative. This combination of manufacturing maturity and clinical track record keeps T cells as the dominant cell type across both approved therapies and active development programs.

NK cells are growing fastest as developers pursue an allogeneic, off-the-shelf alternative to the largely patient-specific T cell therapies available today, since NK cells carry a lower risk of graft-versus-host complications when sourced from a donor rather than the patient. This property makes NK cell platforms attractive for companies seeking to manufacture therapies in advance and ship them on demand rather than engineering cells individually for each patient. As more developers pursue this off-the-shelf manufacturing model, NK cells are expected to grow faster than the broader cell type mix through 2035.

⮞Cartherics and Catalent announced on April 9, 2026, an expanded commercial license agreement that lets Cartherics use Catalent's cGMP-compliant iPSC line to manufacture and commercialize iPSC-derived CAR-NK therapies, including its lead candidate CTH-401, with incentives to use Catalent as its CDMO for late-stage trials and commercial supply. Agreements of this kind show manufacturing partners building supply routes for off-the-shelf NK cell therapies.

By Product, Consumables Dominates the Immune Cell Engineering Market and Software & Services Grows Fastest

Consumables hold the largest product share because the reagents, culture media and engineering kits used to modify immune cells are recurring purchases tied directly to the volume of cells being processed, making them the steadiest revenue stream regardless of which specific cell therapy program a customer is pursuing. Established life sciences suppliers maintain broad reagent catalogs that let customers source engineering materials without committing to a single instrument platform. This repeat-purchase pattern keeps consumables ahead of instruments and software in total revenue even as manufacturing volumes scale.

Software & Services is growing fastest as cell therapy developers increasingly need specialized manufacturing, analytical and data management support to run increasingly complex engineering and quality control workflows across multiple simultaneous programs. Contract development and manufacturing organizations offering full-service support let smaller biotechnology developers access engineering capability without building their own manufacturing teams or hiring additional specialized staff. As more developers adopt this outsourced model for complex engineering work, software and services is expected to grow faster than the broader product mix through 2035.

⮞STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine announced on July 8, 2026, a partnership under which STEMCELL will manufacture and distribute research-use-only iPSC lines derived from LineaBio's GMP lines and offer the matched GMP lines to developers worldwide. Supply of standardized starting materials of this kind illustrates the recurring demand for cell sources and consumables that keeps this product segment ahead.

By Disease Indication, Cancer Dominates the Immune Cell Engineering Market and Autoimmune Diseases Grows Fastest

Cancer holds the largest disease indication share because every currently approved engineered cell therapy targets a blood cancer, and the large pipeline of follow-on programs extending this approach to solid tumors continues to concentrate development activity in oncology ahead of other disease areas. Established reimbursement pathways for approved CAR-T cancer therapies give pharmaceutical developers a clearer commercial template to follow than in less-established indications where coverage decisions remain unsettled. This combination of approved precedent and active pipeline expansion keeps cancer as the dominant disease indication by a wide margin.

Autoimmune diseases are growing fastest as early clinical data showing engineered T cell therapies can deplete disease-driving immune cells in conditions such as lupus has drawn substantial new pharmaceutical investment into this indication. Several large acquisitions of autoimmune-focused cell and T cell engager developers over the past year reflect this growing strategic interest. As more pharmaceutical companies redirect engineering platforms originally built for cancer toward autoimmune disease, this indication is expected to grow faster than the broader disease indication mix through 2035.

⮞Cellares and Cabaletta Bio announced on April 30, 2026, a 10-year commercial supply agreement for rese-cel, an autologous CAR-T therapy in development for autoimmune diseases, to be produced on Cellares' automated Cell Shuttle platform. Long-term manufacturing commitments of this kind show autoimmune CAR-T programs moving toward commercial-scale supply planning.

By End Use, Pharmaceutical and Biotechnology Companies Dominates the Immune Cell Engineering Market and Contract Research Organizations Grows Fastest

Pharmaceutical and biotechnology companies account for the largest end-use share because they run the largest number of engineering programs tied directly to active drug development pipelines, each requiring extensive process development, manufacturing scale-up and quality testing before a candidate reaches clinical trials. Internal engineering groups at larger companies maintain dedicated budgets for this work across multiple simultaneous cell therapy programs, unlike academic laboratories operating on smaller, project-specific grants. This concentration of well-funded, recurring engineering activity keeps pharmaceutical and biotechnology companies as the largest end-use category.

Contract Research Organizations are the fastest-growing end-use category as more biotechnology companies, particularly smaller ones without in-house engineering capability, outsource process development, analytical testing and production support entirely rather than building internal teams from scratch. This outsourced model lets developers advance engineered cell programs without committing capital to dedicated facilities and specialized staff. As more biotechnology companies adopt it, Contract Research Organizations are expected to grow faster than the broader end-use mix through 2035.

⮞Charles River Laboratories announced on January 21, 2026, a manufacturing collaboration with Gazi University Faculty of Medicine under which it will supply research-grade, animal component-free AAV plasmids and support in vitro efficacy studies for a rare inherited disorder. Outsourced plasmid and development support of this kind illustrates the services that smaller developers and academic groups buy from contract providers rather than building in-house.

Regional Analysis:

North America Immune Cell Engineering Market Insights

With a share of 40.50% in 2025, North America led the market. The United States anchors regional demand through its dense concentration of pharmaceutical developers, academic cancer centers and specialized cell therapy manufacturing sites, while Canada contributes through government-funded biomanufacturing research institutes. Commercial sales growth from approved CAR-T therapies originating from U.S. developers continues to reinforce pharmaceutical investment in engineering platforms for new indications. A deep base of established life sciences tool suppliers headquartered in the region keeps order lead times for engineering reagents and manufacturing components shorter than in most other markets.

Growing contract manufacturing capacity is letting smaller regional biotechnology companies access immune cell engineering without building internal teams. Limited U.S. manufacturing capacity for certain viral vectors and specialized reagents can extend lead times during periods of unusually high program activity. Even so, the region's pharmaceutical research depth and clinical validation keep North America ahead of other regions in overall immune cell engineering market size.

⮞Oxford Biomedica announced on February 4, 2026, a multi-year commercial supply agreement with Bristol Myers Squibb to manufacture lentiviral vectors for its CAR-T programs at facilities in Oxford, UK, and Durham, North Carolina. Commercial vector supply from a North American site reflects the manufacturing capacity that regional CAR-T developers depend on.

Asia Pacific Immune Cell Engineering Market Insights

Asia Pacific is the second-largest regional market, with notable activity concentrated in China, Japan, South Korea and India. China anchors regional demand through its large base of local CAR-T developers and expanding regulatory approvals for new indications, while Japan contributes through established life sciences tool makers with strong single-cell and genomics product portfolios. South Korea adds further activity through specialized cell therapy developers, and India is adding manufacturing capacity as local contract development and manufacturing organizations expand into cell and gene therapy. Government-backed biotechnology investment programs across several regional markets are accelerating local engineering capability that might otherwise lag behind demand.

Expanding local regulatory approvals for engineered cell therapies, including recent approvals extending CAR-T therapy beyond blood cancer, are broadening the disease indications driving regional engineering investment. Growing local manufacturing of engineering reagents and components is reducing regional customers' reliance on imported products. Inconsistent reimbursement pathways for engineered cell therapies across individual countries in the region can complicate how developers plan commercial launches. Even so, the region's expanding local developer base and regulatory momentum keep Asia Pacific as the fastest-growing region for immune cell engineering through 2035.

⮞Takara Bio announced on July 21, 2026, a basic agreement with Sumitomo Chemical, Sumitomo Pharma and their joint venture S-RACMO on the succession of its GMP-compliant cell processing CDMO business, with S-RACMO expected to expand its CDMO operations on Takara Bio's cell processing platform. Takara Bio plans to focus its remaining CDMO business on nucleic acids, plasmids, proteins, enzymes and viral vectors. The agreement shows contract cell processing capacity being reorganized across the region.

Europe Immune Cell Engineering Market Insights

Europe is the third-largest regional market, with notable demand concentrated in Germany, the United Kingdom and France. Germany anchors regional demand through its concentration of established life sciences tool manufacturers and specialized cell and gene therapy component suppliers, while the United Kingdom and France contribute through academic cancer research centers and pharmaceutical research hubs. Coordinated European regulatory pathways for advanced therapy medicinal products are supporting continued clinical development of engineered cell therapies across the region. Established European contract manufacturing organizations maintain close working relationships with regional pharmaceutical customers running cell therapy programs.

Expanding European manufacturing capacity for cell and gene therapy components is reducing regional developers' reliance on capacity located outside the region. Growing collaboration between academic cancer centers and pharmaceutical companies is extending engineering research capacity beyond what either could support independently. Slower regional biotechnology funding growth compared with North America and Asia Pacific is moderating the pace of new manufacturing capacity investment. Even so, sustained manufacturing investment and established pharmaceutical research hubs support continued, steady growth for immune cell engineering across European markets through 2035.

⮞Sartorius opened a new competence center for cell and gene therapy components on May 22, 2026, in Freiburg, Germany, representing an investment of approximately USD 160 million that more than doubles its manufacturing capacity for cytokines, growth factors and other critical materials. Investment of this scale in dedicated European manufacturing capacity reflects sustained supplier confidence in long-term regional demand for immune cell engineering components.

MEA & Latin America Immune Cell Engineering Market Insights

The Middle East and Africa is a smaller but rapidly growing market for immune cell engineering, with Saudi Arabia and the United Arab Emirates leading regional activity as flagship hospitals and state-backed investment programs build out local cell and gene therapy manufacturing capability, while South Africa contributes through academic research institutes with established oncology programs. International life sciences tool suppliers are expanding distribution partnerships across Gulf countries as local manufacturing and clinical programs grow. Limited local engineering reagent manufacturing capacity keeps the region reliant on imported materials even as regional investment accelerates from a comparatively small starting point.

Latin America adds demand through growing academic cancer research and an expanding contract manufacturing presence, with Brazil leading regional activity followed by Mexico, Argentina and Colombia. International manufacturing technology providers are extending automated cell and gene therapy production capability into the region to support local developers without requiring them to build manufacturing expertise from scratch. Local reagent and component manufacturing capacity remains limited across the region, and currency volatility complicates long-term component sourcing agreements for multinational suppliers. Even so, expanding manufacturing access and academic research investment support a steady increase in regional immune cell engineering demand through 2035.

⮞The Abu Dhabi Stem Cells Center and Miltenyi Biomedicine signed a memorandum of understanding, reported on October 26, 2026, for scientific and technical cooperation on developing and manufacturing CAR-T therapies in the UAE, with Miltenyi supporting its viral vector and anti-CD19 CAR technologies. The agreement reflects efforts to build local cell therapy manufacturing capability in the Gulf and reduce reliance on overseas treatment.

Market Dynamics:

Growth Drivers: Reagent and instrument demand from life sciences tool suppliers is expanding

Demand for the reagents, instruments and consumables that underpin immune cell engineering continues to grow as more pharmaceutical and biotechnology developers advance engineered cell therapy programs from research into clinical and commercial manufacturing. This steady expansion in program-level demand supports continued investment by established tool suppliers in new reagent formulations and higher-throughput manufacturing platforms. Suppliers that can keep pace with this demand through expanded manufacturing capacity are well positioned to capture a growing share of recurring consumable and instrument purchases.

A second driver is the commercial validation provided by approved CAR-T therapies posting strong sales growth, which demonstrates to pharmaceutical developers that engineering investment can translate into regulatory approval and durable commercial revenue. This validation is encouraging more companies to invest earlier in engineering platforms for new cell types and disease indications rather than relying solely on the established T cell and blood cancer template. As more engineered cell therapies advance through development and toward approval in additional indications, this validation effect is expected to reinforce broader engineering demand across the industry.

⮞MaxCyte announced on July 21, 2026, a multi-platform technology license partnership with Genentech that gives access to its ExPERT GTx platform and additional technologies across research, clinical development and cGMP manufacturing workflows for ex vivo cell engineering. Licensing of engineering tools of this kind reflects the reagent and instrument demand that continues to expand with cell therapy programs.

Restraints: Supplier consolidation and manufacturing capacity constraints create operational uncertainty

Ongoing consolidation among established life sciences tool suppliers is narrowing the number of independent vendors that pharmaceutical and biotechnology customers can choose from for engineering reagents, instruments and manufacturing components, which can reduce negotiating leverage and increase switching costs for customers reliant on a single supplier's product line. Smaller biotechnology developers with limited purchasing volume are particularly exposed to this consolidation compared with larger, better-resourced pharmaceutical companies that can negotiate long-term supply agreements. This supplier concentration can slow adoption of alternative engineering approaches until comparable products become available from multiple vendors.

Limited manufacturing capacity for specialized components such as viral vectors and certain engineering reagents also exposes developers to order backlogs and extended lead times during periods of unusually high program activity, since few alternative suppliers can quickly absorb overflow orders for custom manufacturing. This capacity constraint can be particularly disruptive for time-sensitive clinical programs that cannot easily substitute a different reagent source mid-program. Smaller academic and biotechnology customers with limited purchasing leverage are more exposed to these disruptions than large, well-resourced pharmaceutical companies.

⮞Merck KGaA agreed on June 26, 2026, to acquire Bio-Techne for approximately USD 11.3 billion, a deal aimed at strengthening its life sciences division with an expanded portfolio of advanced research and analytical technologies serving genomics and cell and gene therapy researchers. Consolidation of this scale among established life sciences tool suppliers illustrates the kind of supplier concentration that can affect customer choice and pricing across the immune cell engineering supply chain.

Opportunities: Expanding manufacturing access in emerging markets is widening the addressable market

Automated, modular manufacturing technology that reduces the skilled labor and capital investment needed to produce engineered cell therapies is creating an opportunity for manufacturing technology providers to extend their addressable market into regions that previously lacked the infrastructure to support local production. Providers that can offer accessible, pre-validated manufacturing platforms suited to smaller-scale regional operations are well positioned to establish early relationships with developers in these emerging markets ahead of broader market maturity. As more regions build out this kind of accessible manufacturing capability, this opportunity is expected to grow alongside, rather than instead of, traditional engineering reagent and instrument demand in established markets.

A second opportunity lies in extending engineered cell therapy development beyond oncology into autoimmune disease and other new indications, which draws in a wider pool of pharmaceutical developers and research institutions that had not previously invested in cell engineering platforms. Suppliers and manufacturing partners that can support this broader set of disease indications with flexible, adaptable platforms are well positioned to capture demand from developers entering the field for the first time. This growing base of new entrants exploring cell engineering for non-oncology indications lowers the barrier for established suppliers to expand their addressable market beyond their traditional oncology-focused customer base.

⮞Sartorius launched the Eveo Cell Therapy Platform on March 16, 2026, a modular closed system for automated, multi-parallel production of autologous cell therapies; in a pilot with ElevateBio, one operator processed eight patient batches in cleanroom space that normally handles two. Order intake is planned to begin in September 2026, with first deliveries expected in 2027. Automation of this kind reduces the labor and footprint needed for local production, supporting the opportunity for manufacturing technology providers.

Immune Cell Engineering Market Key Players:

• Thermo Fisher Scientific Inc.

• Danaher Corporation

• Merck KGaA

• Lonza Group AG

• Sartorius AG

• Miltenyi Biotec B.V. & Co. KG

• Terumo Blood and Cell Technologies

• Takara Bio Inc.

• Bio-Techne Corporation

• Agilent Technologies, Inc.

• Bio-Rad Laboratories, Inc.

• STEMCELL Technologies Inc.

• MaxCyte, Inc.

• Catalent, Inc.

• Charles River Laboratories International, Inc.

• AGC Biologics

• Oxford Biomedica plc

Immune Cell Engineering Market Report Scope: